Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Transcript (slightly modified)
How do different healthcare stakeholders view value differently?
Different stakeholders view value differently in a few ways. Patients, for instance, when they think about value, they are thinking about “how does this therapy help me achieve my life objectives?” Payers, on the other hand, are think about value and then designing coverage policies accordingly in terms of how to give patients access to the therapies that meet those life objectives, but they also have to balance that with their fiduciary responsibility.
Essentially, this is an issue of balancing patient access and costs. Patients have a bit of a more individual viewpoint when thinking about value, whereas payers have to think on a more population based level.
How can these differing viewpoints be taken into account as new value assessment frameworks are created?
Different viewpoints can be taken into account as more value assessment frameworks are created by tailoring them to the specific end-user. Secondly, by making sure they represent a range of values that account for the spectrum of preferences.
Frameworks for Advancing Health Equity: Health Equity by Design
July 23rd 2024Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Cost Savings From an mHealth Tool for Improving Medication Adherence
October 21st 2024The Wellth smartphone app significantly increased medication adherence and lowered unnecessary health care utilization and costs over 9 months among Medicaid beneficiaries who were self-managing chronic conditions.
Read More